BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018

Conference Report of IDDST-2018

BIT's 16^th Annual Congress of International Drug Discovery Science and Technology-2018 (IDDST-2018) which was held in Boston Marriott Cambridge, Boston, USA on August 16-18, achieved a consummation. Our conference was hosted by BIT Group Global Ltd., co-hosted by Sino-American Pharmaceutical Professionals Association – New England and supported by AISI - American International Standard Institute. The theme of this conference is “Rethinking the Next Big Things in Pharma Innovations". Over 300 honored guests presented at the ceremony and gave brilliant speeches on invitation, among them are Dr. Gregory L. Verdine, Founder, CEO & Erving Professor, FogPharma and LifeMine Therapeutics; Harvard University and Harvard Medical School, USA; Dr. Daryl C. Drummond, Senior Vice President and Head of Research, Merrimack Pharmaceuticals, USA; Dr. Kenneth G. Faulkner, Corporate Vice President, Patient Technology Solutions, PAREXEL, USA; Dr. Qun (Max) Dang, Vice President & Global Head of BD and External Innovation, PR&D, Qilu Pharmaceutical, China; Dr. Tom Mander, Chief Operating Officer, Domainex Ltd., UK, Dr. John Delaney, Executive Director, Discovery Research; Site Head, Amgen British Columbia, Amgen, Inc, USA; …etc.

This annual congress comprised of 3 Parts and 24 sessions following the ceremony, including “Decoding Mechanism of Diseases“, Enabled Technologies for Drug Discovery"; “Next Generation Therapy"; “Current Drug Targets"; "Novel Small Molecule Inhibitors and Agonists"; "Smart DDS"…etc.

This annual conference brought together 300 specialists from 35 countries and areas, which was devoted to the leading issues and popular topics and provide up-to-date information to all over the world. In welcome banquet, all guests appreciated and joined in the brilliant Chinese traditional performances, also expressed sincerely congratulation to successful IDDST-2018. Depending on the warmly support and good suggestions from all of the participants, we are quite confident in organizing IDDST-2019 which would be better and more successful than IDDST-2018. All of us are looking forward to meeting you again in 2019.

Renowned Speakers of IDDST-2018

Dr. Gregory L. Verdine, Professor, Harvard University, USA	Dr. Laszlo Urban, Executive Director, Novartis Institutes for BioMedical Research, USA	Dr. Lawrence Friedhoff, Chief, Research & Development, Roivant Sciences, Inc., USA
Dr. Daryl C. Drummond, Senior Vice President and Head of Research, Merrimack Pharmaceuticals, USA	Dr. Kenneth G. Faulkner, Corporate Vice President, Patient Technology Solutions, PAREXEL, USA	Dr. Qun (Max) Dang, Vice President, PR&D, Institute of Pharmaceutical Research and Development, Qilu Pharmaceutical, China
Dr. John Delaney, Executive Director, Amgen Inc., USA	Dr. Tycho H. Heimbach, Director, PK Sciences, Novartis Pharmaceuticals Corporation, Switzerland	Dr. Naitee Ting, Director, Department of Biostatistics & Data Sciences, Boehringer-Ingelheim Pharmaceuticals Inc., USA
Dr. Shanrong Zhao, Director, Computational Biology and Bioinformatics, Pfizer Worldwide Research & Development, Pfizer, Inc., USA	Dr. Gyungah Jun, Director and Head, Neurogenetics and Integrated Genomics Integrated Human Genomics (IHGx), CCLO-PCHQ, Eisai, Inc., USA	Dr. Nitin Naik, Global Vice President, Life Sciences, Frost & Sullivan, USA
Dr. Dietmar Wolf, Executive Vice President, AnalytiCon Discovery, LCC, Germany	Dr. Kerstin Walke, Head of Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany	Dr. Niclas Nilsson, Head of RD Open Innovation, LEO Pharma A/S, Denmark
Dr. Robert W. Lee, Executive Vice President, Particle Sciences, Inc., USA	Dr. Raul Insa, Founder and CEO, SOM Biotech, Spain	Dr. Alain L. Fymat, President/CEO, International Institute of Medicine and Science California, USA
Dr. Jack T. Rogers, Director of Neurochemistry Laboratory, Massachusetts General Hospital, Harvard University, USA	Dr. Bakhos A. Tannous, Director, Harvard Medical School and Massachusetts General Hospital, USA	Dr. Irwin J. Kurland, Director, Albert Einstein College of Medicine, USA

Programmed chapters at a glance

Stream 0	Open the Glory Hall of Drug Innovators -Registration Day and Ice Breaking Party
Stream 1	Big Mind Bay -Rethinking the Next Big Things in Drug Discovery
Stream 2	Creative Explorer’s Hubs -New Paradigms in Next Generation Drug Discovery
Stream 3	Industrial Art Gallery -Arts in Billion Dollar Molecules and Next Generation Therapy
Stream 4	Drug Discovery Bazaar -Posters and Exhibits
Stream 5	Joyful Commune -Sharing the Diversities for Common Interests

Past Conference Report

Opening Ceremony

Past Conference Report of IDDST-Japan 2017

BIT's 15^th Annual Congress of International Drug Discovery Science and Technology-Japan 2017 (IDDST-Japan 2017) which was held in Hyatt Regency Osaka, Osaka, Japan on July 25-27, achieved a consummation. The theme of this conference is “Dedicated to Accelerating Drug Innovation". Over 400 honored guests presented at the ceremony and gave brilliant speeches on invitation, among them are 2010 Nobel Prize Laureate in Chemistry Dr. Ei-ichi Negishi, H. C. Brown Distinguished Professor of Chemistry in Purdue University; Dr. Howard J. Federoff, Vice Chancellor of Health Affairs and Chief Executive Officer of Health System in University of California, Irvine; Dr. Litao Zhang, Vice President of Bristol-Myers Squibb; Dr. Jan Hoflack, Chief Scientific and Operational Officer of Oncodesign SA; Dr. Akiyoshi Suganuma, Group Officer and President of BA-CFU in Medicine Development Center, Eisai Co., Ltd., Dr. David C. Bunton, CEO of REPROCELL Europe Ltd. …etc.

. . . View more

Analysis of Attendees Last Year

Scenery of Boston

Boston is one of the oldest cities in the United States, founded on the Shawmut Peninsula in 1630 by Puritan settlers from England. The area's many colleges and universities make Boston an international center of higher education, including law, medicine, engineering, and business, and the city is considered to be a world leader in innovation and entrepreneurship, with nearly 2,000 start-ups. Boston's economic base also includes finance, professional and business services, biotechnology, information technology, and government activities.